Thor Medical ASA (TRMED) - Total Assets
Based on the latest financial reports, Thor Medical ASA (TRMED) holds total assets worth Nkr561.00 Million NOK (≈ $59.03 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore TRMED operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Thor Medical ASA - Total Assets Trend (2020–2024)
This chart illustrates how Thor Medical ASA's total assets have evolved over time, based on quarterly financial data. See Thor Medical ASA (TRMED) shareholders funds for net asset value and shareholders' equity analysis.
Thor Medical ASA - Asset Composition Analysis
Current Asset Composition (December 2024)
Thor Medical ASA's total assets of Nkr561.00 Million consist of 31.4% current assets and 68.6% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr1.00K | 29.8% |
| Accounts Receivable | Nkr6.50 Million | 1.6% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr1.43 Million | 0.3% |
| Intangible Assets | Nkr245.82 Million | 59.3% |
| Goodwill | Nkr37.18 Million | 9.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Thor Medical ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Thor Medical ASA (TRMED) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Thor Medical ASA's current assets represent 31.4% of total assets in 2024, a decrease from 98.2% in 2020.
- Cash Position: Cash and equivalents constituted 29.8% of total assets in 2024, down from 93.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 67.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 59.3% of total assets.
Thor Medical ASA Competitors by Total Assets
Key competitors of Thor Medical ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Thor Medical ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.87 | 6.48 | 3.63 |
| Quick Ratio | 8.78 | 6.48 | 3.63 |
| Cash Ratio | 0.00 | 5.69 | 3.43 |
| Working Capital | Nkr220.40 Million | Nkr28.50 Million | Nkr272.63 Million |
Thor Medical ASA - Advanced Valuation Insights
This section examines the relationship between Thor Medical ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.69 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | 25.3% |
| Total Assets | Nkr414.40 Million |
| Market Capitalization | $215.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Thor Medical ASA's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Thor Medical ASA's assets grew by 25.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Thor Medical ASA (2020–2024)
The table below shows the annual total assets of Thor Medical ASA from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr414.40 Million ≈ $43.61 Million |
+25.26% |
| 2023-12-31 | Nkr330.83 Million ≈ $34.81 Million |
+201.73% |
| 2022-12-31 | Nkr109.64 Million ≈ $11.54 Million |
-63.04% |
| 2021-12-31 | Nkr296.67 Million ≈ $31.22 Million |
-5.70% |
| 2020-12-31 | Nkr314.61 Million ≈ $33.11 Million |
-- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.